Bridge to Life's VitaSmart™ System Receives NHS Funding Recommendation to Enhance Liver Transplant Outcomes

UK NICE Endorses Routine NHS Funding for the VitaSmart™ System

In a significant breakthrough for liver transplantation technology, the UK's National Institute for Health and Care Excellence (NICE) has issued new guidelines recommending routine funding from the National Health Service (NHS) for the VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) system. Developed by Bridge to Life™ Ltd., a leader in organ preservation and perfusion technologies, this system represents a major advancement in the preservation of deceased donor livers prior to transplantation.

Enhancing Preservation with Innovation

NICE's recommendation comes after a comprehensive evaluation of ex-situ machine perfusion devices, which have demonstrated substantial clinical and economic advantages over traditional static cold storage methods. The findings indicated that hypothermic oxygenated perfusion not only improves graft survival rates but also leads to fewer biliary complications during and after transplantation.

Don Webber, CEO of Bridge to Life™, stated that the NICE recommendation is a pivotal moment in integrating hypothermic oxygenated perfusion as the standard care in liver transplantation. He emphasized that the successful adoption of this technology across Europe over the past decade is a testament to its efficacy and potential for improving patient outcomes.

The Role of VitaSmart™ in Liver Transplants

The VitaSmart™ system is engineered to infuse oxygenated solutions directly into donor livers, ensuring their viability for transplantation. Its design prioritizes operational simplicity, allowing it to be seamlessly adopted in clinical settings without the complexity often associated with other technologies. This ease of use is crucial for surgical teams who can now employ extended-criteria donor organs with confidence, thereby maximizing available resources in liver transplantation.

With its UK NHS funding approval, the VitaSmart™ system signals a new era for transplantation programs, ensuring equitable access to advanced, user-friendly perfusion technology. This advancement allows for more efficient operating room logistics and improved patient outcomes, as noted by Consultant Liver Transplant Surgeon Rebbeca Sanabria Mateos from University Hospitals Birmingham NHS Foundation Trust.

Broadening Access and Advancing Technology

As the VitaSmart™ system gains traction, its availability is expected to expand beyond the UK, with existing markets in the U.S., Europe, Saudi Arabia, and India. Following its recent FDA De Novo clearance, Bridge to Life™ is poised for rapid commercial growth in the American market. This expansion reflects the company's commitment to evidence-based preservation science, which not only facilitates increased organ donation but also enhances the overall efficacy of transplantation procedures.

Conclusion

With NICE's endorsement, the future of liver transplantation looks promising thanks to innovations like the VitaSmart™ Hypothermic Oxygenated Perfusion system. As healthcare providers adopt this cutting-edge technology, patients can expect better outcomes and a more efficient use of donor organs. Bridge to Life™ remains at the forefront of this transformation, dedicated to advancing medical science to improve patient care and save lives worldwide.